Bristol Myers Squibb - Financial News http://www.businesswire.com Business Wire - The global leader in news distribution en Copyright 2009, Business Wire. WebSupport@BusinessWire.com WebSupport@BusinessWire.com Tue, 24 Nov 2009 21:22:29 UT Tue, 24 Nov 2009 21:22:29 UT http://www.businesswire.com Business Wire http://www.businesswire.com Business Wire - The global leader in news distribution http://www.businesswire.com/images/bwlogo_small.gif 100 36 Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference Tue, 10 Nov 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at a Credit Suisse healthcare conference on Thursday, November 12, 2009 in Phoenix, Arizona. Jean-Marc Huet, executive vice president and chief financial officer of Bristol-Myers Squibb, will make a formal presentation about the company at 10:30 a.m. ET. Investors and the general public are invited to listen to a live webcast of the presentation at http://investor.bms.com. Materials related to the presentation will b http://www.businesswire.com/news/bms/20091110005575/en 20091110005575en Medarex, Inc. Announces Expiration of Offer to Repurchase its 2.25% Convertible Senior Notes due May 15, 2011 Mon, 26 Oct 2009 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Medarex, Inc., a wholly owned subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), announced today that its offer to repurchase its 2.25% Convertible Senior Notes due May 15, 2011 (the “Convertible Notes”) expired on October 23, 2009 pursuant to terms of the notice of change in control to holders of the Convertible Notes dated September 23, 2009. The trustee for the Convertible Notes has advised Medarex that no Convertible Notes were tendered in the offe http://www.businesswire.com/news/bms/20091026005686/en 20091026005686en Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter Thu, 22 Oct 2009 11:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported strong sales and earnings growth for the third quarter 2009. “The performance in the third quarter of 2009 clearly shows the results of our outstanding business performance, disciplined financial management and overall strategic execution,” said James M. Cornelius, chairman and chief executive officer. “We are transforming Bristol-Myers Squibb into a BioPharma leader and the recent approval and la http://www.businesswire.com/news/bms/20091022005159/en 20091022005159en Study Finds That ONGLYZA™ (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus Mon, 5 Oct 2009 13:39:00 UT PRINCETON, N.J. and LONDON--(BUSINESS WIRE)--Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA™ (saxagliptin) 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with JANUVIA® (sitagliptin) 100 mg per day in reducing HbA1c from baseline. In this study, overall adverse events were reported at a s http://www.businesswire.com/news/bms/20091005005886/en 20091005005886en Bristol-Myers Squibb to Announce Results for the Third Quarter of 2009 on October 22 Fri, 2 Oct 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2009 on Thursday, October 22. During a 10:30 a.m. (ET) conference call on October 22, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing 913-312-1296, confirmation code: 4883550. Materials related to th http://www.businesswire.com/news/bms/20091002005396/en 20091002005396en Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in Asia Pacific (Excl. China & Japan) and Shares in PT Bristol-Myers Squibb Indonesia Tbk Wed, 16 Sep 2009 03:00:00 UT JAKARTA, Indonesia--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has reached an agreement for the sale of its OTC assets in Asia Pacific (excluding China and Japan) to Taisho Pharmaceutical Co., Ltd. (“Taisho”). Pursuant to the terms of the definitive agreement, Taisho will acquire from Bristol-Myers Squibb certain product registrations, trademarks and related assets of selected pharmaceutical and over-the-counter products sold primarily in Indone http://www.businesswire.com/news/bms/20090915006796/en 20090915006796en Bristol-Myers Squibb to Present at Morgan Stanley Global Healthcare Unplugged Conference Fri, 11 Sep 2009 13:45:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, 2009 in New York. Lamberto Andreotti, president and chief operating officer of Bristol-Myers Squibb, will make a presentation on the company at 2:10 p.m. ET on September 14. Investors and the general public are invited to listen to a live webcast of the presentation at http://investor.bms.com. An archived edition of the presentation http://www.businesswire.com/news/bms/20090911005397/en 20090911005397en Bristol-Myers Squibb Announces Dividend Wed, 9 Sep 2009 20:05:00 UT NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value Common Stock of the corporation. The quarterly dividend will be payable on November 2, 2009 to stockholders of record at the close of business on October 2, 2009. The Directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable De http://www.businesswire.com/news/bms/20090909006316/en 20090909006316en Bristol-Myers Squibb Completes Acquisition of Medarex, Inc. Tue, 1 Sep 2009 21:11:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced $2.4 billion acquisition of Medarex, Inc. (NASDAQ: MEDX) (“Medarex”). As a result of the transaction, Medarex has become a wholly-owned subsidiary of Bristol-Myers Squibb. Bristol-Myers Squibb initiated on July 28, 2009 a cash tender offer to purchase all outstanding shares of common stock of Medarex for $16.00 per share. The tender offer period expired a http://www.businesswire.com/news/bms/20090901006647/en 20090901006647en Bristol-Myers Squibb Completes Tender Offer for Medarex, Inc. Tue, 1 Sep 2009 12:10:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the depositary for its tender offer for all the outstanding common stock of Medarex has advised that, as of the expiration of the subsequent offering period, shareholders of Medarex, Inc. (NASDAQ: MEDX) (“Medarex”) tendered approximately 120,417,467 shares, representing, together with the 2,879,223 shares of Medarex common stock owned by Bristol-Myers Squibb since January 2005, approximately 90.7 http://www.businesswire.com/news/bms/20090901005788/en 20090901005788en Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. with 87.7% of Shares Tendered; Announces Subsequent Offering Period Thu, 27 Aug 2009 12:10:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the initial tender offer, through its wholly owned subsidiary, Puma Acquisition Corporation, for all outstanding shares of common stock of Medarex, Inc. (NASDAQ: MEDX) (“Medarex”) expired at midnight (New York City time) on August 26, 2009, and was not extended. The depositary for the tender offer has advised Bristol-Myers Squibb that, as of the expiration of the initial tender offer, shareholder http://www.businesswire.com/news/bms/20090827005479/en 20090827005479en Bristol-Myers Squibb Begins Tender Offer to Acquire Medarex, Inc. Tue, 28 Jul 2009 09:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) is commencing today, through its wholly owned subsidiary Puma Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common http://www.businesswire.com/news/bms/20090728005309/en 20090728005309en Excellent Performance Highlights Second Quarter for Bristol-Myers Squibb Thu, 23 Jul 2009 11:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported sales and earnings growth for the second quarter 2009. http://www.businesswire.com/news/bms/20090723005256/en 20090723005256en Bristol-Myers Squibb to Announce Results for the Second Quarter and First Six Months of 2009 on July 23 Thu, 9 Jul 2009 20:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter and first six months of 2009 on Thursday, July 23. During a 10:30 a.m. (ET) conference call, company http://www.businesswire.com/news/bms/20090709005933/en 20090709005933en Bristol-Myers Squibb Announces Dividend Wed, 10 Jun 2009 20:00:00 UT NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value Common Stock of the http://www.businesswire.com/news/bms/20090610006032/en 20090610006032en Bristol-Myers Squibb to Present at Goldman Sachs Global Healthcare Conference Wed, 10 Jun 2009 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2009 in New York. Elliott Sigal, M.D., Ph.D., executive vice http://www.businesswire.com/news/bms/20090610005064/en 20090610005064en Bristol-Myers Squibb to Present at Bernstein Strategic Decisions Conference Tue, 26 May 2009 17:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bernstein Strategic Decisions Conference on Wednesday, May 27, 2009 in New York. Jim Cornelius, chairman and chief executive http://www.businesswire.com/news/bms/20090526005945/en 20090526005945en Bristol-Myers Squibb to Present at Deutsche Bank Healthcare Conference Mon, 18 May 2009 19:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Deutsche Bank Healthcare Conference on Tuesday, May 19, 2009 in Boston. Jean-Marc Huet, executive vice president and chief http://www.businesswire.com/news/bms/20090518006372/en 20090518006372en Bristol-Myers Squibb to Present at Bank of America and Merrill Lynch Health Care Conference Tue, 12 May 2009 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America and Merrill Lynch Health Care Conference on Wednesday, May 13, 2009 in New York. Lamberto Andreotti, president and http://www.businesswire.com/news/bms/20090512005224/en 20090512005224en Bristol-Myers Squibb to Present at Bernstein Pharmaceutical Emerging Markets Conference Tue, 5 May 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will present at the Bernstein Pharmaceutical Emerging Markets Conference on Wednesday, May 6, 2009. John Celentano, president of Emerging Markets and http://www.businesswire.com/news/bms/20090505005987/en 20090505005987en Bristol-Myers Squibb Invites Public to Listen to Webcast of 2009 Annual Meeting Wed, 29 Apr 2009 14:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) invites investors and the general public to listen to a webcast of its annual meeting with stockholders at 9:45 a.m. ET on Tuesday, May 5, 2009. In http://www.businesswire.com/news/bms/20090429005068/en 20090429005068en Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic Initiatives Tue, 28 Apr 2009 11:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced first quarter results which included excellent financial performance and successful execution of two key strategic initiatives. The http://www.businesswire.com/news/bms/20090428005243/en 20090428005243en Bristol-Myers Squibb to Announce Results for the First Quarter of 2009 on April 28 Mon, 20 Apr 2009 20:09:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2009 on Tuesday, April 28. During an 11 a.m. (ET) conference call on April 28, company executives will http://www.businesswire.com/news/bms/20090420006464/en 20090420006464en Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY® and Establishment of an Oncology Collaboration with Otsuka Mon, 6 Apr 2009 08:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced an agreement with Otsuka Pharmaceutical Co., Ltd. (hereafter, “Otsuka”) to extend the U.S. portion of the http://www.businesswire.com/news/bms/20090406005491/en 20090406005491en Bristol-Myers Squibb to Present at Healthcare Conference Mon, 16 Mar 2009 19:46:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009 in Boston. Brian Daniels, senior vice president, http://www.businesswire.com/news/bms/20090316006378/en 20090316006378en Bristol-Myers Squibb to Present at Healthcare Conference Mon, 9 Mar 2009 20:50:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Barclay’s Capital Global Healthcare Conference on Tuesday, March 10, 2009 in Miami Beach, FL. Jean-Marc Huet, executive vice http://www.businesswire.com/news/bms/20090309006183/en 20090309006183en Bristol-Myers Squibb Statement on Mead Johnson Nutrition Company IPO Wed, 11 Feb 2009 15:06:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) issued the following statement on today’s initial public offering of Mead Johnson Nutrition Company (NYSE:MJN): http://www.businesswire.com/news/bms/20090211005864/en 20090211005864en Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb Tue, 27 Jan 2009 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY): http://www.businesswire.com/news/bms/20090127005474/en 20090127005474en Bristol-Myers Squibb To Announce Results For The Fourth Quarter And Full Year Of 2008 On January 27 Fri, 16 Jan 2009 14:20:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2008 on Tuesday, January 27. During a 10:30 a.m. (ET) conference call on January 27, http://www.businesswire.com/news/bms/20090116005366/en 20090116005366en Bristol-Myers Squibb to Present at Healthcare Conference Tue, 13 Jan 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at a J.P. Morgan healthcare conference on Wednesday, January 14, 2009 in San Francisco. Elliott Sigal, M.D., Ph.D., executive vice http://www.businesswire.com/news/bms/20090113005081/en 20090113005081en Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound Mon, 12 Jan 2009 21:00:00 UT PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon http://www.businesswire.com/news/bms/20090112006312/en 20090112006312en Bristol-Myers Squibb Announces Dividend Thu, 18 Dec 2008 22:15:00 UT NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value Common Stock of the http://www.businesswire.com/news/bms/20081218006205/en 20081218006205en New Data Demonstrate Significant Improvement in Progression-Free Survival for Triple Negative Metastatic Breast Cancer Patients Treated with IXEMPRA™ Plus Capecitabine Fri, 12 Dec 2008 23:00:00 UT SAN ANTONIO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from studies of IXEMPRA™ (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub http://www.businesswire.com/news/bms/20081212005537/en 20081212005537en Sanofi-Aventis and Bristol-Myers Squibb Prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix® Patent Infringement Case Fri, 12 Dec 2008 17:30:00 UT PARIS & NEW YORK--(BUSINESS WIRE)--Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) announced today that the U.S. Court of Appeals for the Federal http://www.businesswire.com/news/bms/20081212005480/en 20081212005480en Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Fri, 12 Dec 2008 10:54:00 UT PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Exelixis, Inc. (Nasdaq: EXEL) today announced a global collaboration covering two novel molecules for cancer http://www.businesswire.com/news/bms/20081212005212/en 20081212005212en ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration Mon, 8 Dec 2008 15:05:00 UT NEW YORK--(BUSINESS WIRE)--ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have submitted an application to the http://www.businesswire.com/news/bms/20081208005847/en 20081208005847en Bristol-Myers Squibb and AstraZeneca Announce Expansion of Worldwide Collaboration to Develop and Commercialize Dapagliflozin in Japan Mon, 8 Dec 2008 12:30:00 UT PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced expansion of their worldwide collaboration to include the development and http://www.businesswire.com/news/bms/20081208005216/en 20081208005216en Bristol-Myers Squibb to Present at Healthcare Conference Thu, 13 Nov 2008 14:00:00 UT NEW YORK--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20081113005675/en 20081113005675en Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal Thu, 6 Nov 2008 07:00:00 UT PARIS AND PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the http://www.businesswire.com/news/bms/20081105006299/en 20081105006299en New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B Sun, 2 Nov 2008 16:00:00 UT SAN FRANCISCO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced data from two separate cohort evaluations, in which long-term treatment with BARACLUDE http://www.businesswire.com/news/bms/20081102005040/en 20081102005040en ERBITUX(R) Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration Thu, 30 Oct 2008 20:55:00 UT NEW YORK--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20081030006497/en 20081030006497en Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis Tue, 28 Oct 2008 00:39:00 UT SAN FRANCISCO--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20081027006546/en 20081027006546en Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With ORENCIA(R) (abatacept) and Methotrexate (MTX) Achieved DAS28 (CRP)-Defined Remission Compared to MTX Alone Mon, 27 Oct 2008 22:45:00 UT SAN FRANCISCO--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20081027006493/en 20081027006493en 96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients Sun, 26 Oct 2008 16:30:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week data from the CASTLE study, in which 74 percent of the 440 patients in the REYATAZ http://www.businesswire.com/news/bms/20081026005064/en 20081026005064en Bristol-Myers Squibb Continues Excellent Financial Performance Led By Double-Digit Global Net Sales Growth and Strong Earnings Results Thu, 23 Oct 2008 11:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY): http://www.businesswire.com/news/bms/20081023005208/en 20081023005208en Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment Wed, 22 Oct 2008 21:00:00 UT NEW YORK--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20081022006417/en 20081022006417en Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner Mon, 6 Oct 2008 15:41:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) announced today that it will acquire ImClone Systems (NASDAQ:IMCL) for $70 per share, or approximately $6.5 billion. http://www.businesswire.com/news/bms/20081006006142/en 20081006006142en Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share Mon, 22 Sep 2008 23:01:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it is increasing its initial offer for ImClone Systems Incorporated (NASDAQ: IMCL) and intends to http://www.businesswire.com/news/bms/20080922006657/en 20080922006657en ERBITUX(R) Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer Mon, 22 Sep 2008 19:00:00 UT NEW YORK--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20080922006435/en 20080922006435en Bristol-Myers Squibb Announces Filing of IPO Registration Statement for Mead Johnson Nutrition Company Mon, 15 Sep 2008 21:16:00 UT NEW YORK--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20080915006704/en 20080915006704en Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year Mon, 15 Sep 2008 14:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20080915005868/en 20080915005868en Bristol-Myers Squibb to Present at Healthcare Conference Mon, 15 Sep 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20080915005532/en 20080915005532en Bristol-Myers Squibb Submits Letter to ImClone Board of Directors Thu, 11 Sep 2008 14:54:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) submitted the following letter to ImClone Systems Incorporated (NASDAQ: IMCL) Board of Directors today: http://www.businesswire.com/news/bms/20080911005644/en 20080911005644en Study Published in New England Journal of Medicine Shows ERBITUX(R) Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer Wed, 10 Sep 2008 21:02:00 UT NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb http://www.businesswire.com/news/bms/20080910006395/en 20080910006395en Bristol-Myers Squibb Announces Dividend Tue, 9 Sep 2008 20:15:00 UT NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of http://www.businesswire.com/news/bms/20080909006570/en 20080909006570en ONGLYZATM (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in Treatment Naïve People With Type 2 Diabetes Tue, 9 Sep 2008 12:00:00 UT ROME--(BUSINESS WIRE)--Results from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA™ (saxagliptin), an investigational http://www.businesswire.com/news/bms/20081211006257/en 20081211006257en ONGLYZA(TM) (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in Treatment Naive People With Type 2 Diabetes Tue, 9 Sep 2008 10:01:00 UT ROME--(BUSINESS WIRE)--Results from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated http://www.businesswire.com/news/bms/20080909005718/en 20080909005718en ONGLYZA(TM) (saxagliptin) Demonstrated Significant Improvements Across Key Measures of Glucose Control When Added to a Sulfonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes Mon, 8 Sep 2008 11:00:00 UT ROME--(BUSINESS WIRE)--Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated http://www.businesswire.com/news/bms/20080908005647/en 20080908005647en Bristol-Myers Squibb and AstraZeneca to Hold Investor Teleconference to Discuss EASD Highlights Wed, 3 Sep 2008 13:15:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca http://www.businesswire.com/news/bms/20080903005818/en 20080903005818en Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights Thu, 28 Aug 2008 16:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a conference call at 8:30 a.m. (ET) on Wednesday, September 3 http://www.businesswire.com/news/bms/20080828005701/en 20080828005701en Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma Tue, 19 Aug 2008 20:00:00 UT PRINCETON, N.J. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and http://www.businesswire.com/news/bms/20080819006170/en 20080819006170en Bristol-Myers Squibb Announces Completion of ConvaTec Divestiture Fri, 1 Aug 2008 17:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Nordic Capital Fund VII and Avista Capital Partners http://www.businesswire.com/news/bms/20080801005599/en 20080801005599en Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash Thu, 31 Jul 2008 11:59:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has proposed to enter into an agreement to acquire ImClone Systems Incorporated (NASDAQ: IMCL), a http://www.businesswire.com/news/bms/20080731005617/en 20080731005617en Bristol-Myers Squibb Continues Strong Financial Performance Led by Double-Digit Global Sales Growth Thu, 24 Jul 2008 11:29:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported very strong sales and earnings growth for the second http://www.businesswire.com/news/bms/20080724005186/en 20080724005186en Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes Wed, 23 Jul 2008 12:00:00 UT PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and http://www.businesswire.com/news/bms/20080723005568/en 20080723005568en Bristol-Myers Squibb to Announce Results for the Second Quarter of 2008 on July 24 Tue, 15 Jul 2008 17:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2008 on http://www.businesswire.com/news/bms/20080715005964/en 20080715005964en Bristol-Myers Squibb Completes Acquisition of Kosan Biosciences Incorporated Thu, 26 Jun 2008 21:39:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced $190 million acquisition of Kosan Biosciences http://www.businesswire.com/news/bms/20080626006166/en 20080626006166en Bristol-Myers Squibb Completes Tender Offer for Kosan Biosciences Incorporated Thu, 26 Jun 2008 12:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that stockholders of Kosan Biosciences Incorporated (NASDAQ: KOSN) ( http://www.businesswire.com/news/bms/20080626005485/en 20080626005485en Data from Phase II Exploratory Study Suggest That ORENCIA(R) (abatacept) May Delay Development of Rheumatoid Arthritis in Adults with Undifferentiated Inflammatory Arthritis Fri, 13 Jun 2008 16:37:00 UT PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results from an exploratory Phase II study of 56 http://www.businesswire.com/news/bms/20080613005549/en 20080613005549en ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis Thu, 12 Jun 2008 12:02:00 UT PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of radiographic analyses from the AIM ( http://www.businesswire.com/news/bms/20080612005525/en 20080612005525en Bristol-Myers Squibb Announces Dividend Tue, 10 Jun 2008 20:30:00 UT NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of http://www.businesswire.com/news/bms/20080610006528/en 20080610006528en ONGLYZA(TM) (saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes Sat, 7 Jun 2008 17:03:00 UT SAN FRANCISCO--(BUSINESS WIRE)--Results from a 24-week Phase III study presented at the 68th American Diabetes Association Annual Scientific Sessions demonstrated http://www.businesswire.com/news/bms/20080607005025/en 20080607005025en Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ADA Highlights Thu, 5 Jun 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a conference call at 8:30 a.m. (ET) on Wednesday, June http://www.businesswire.com/news/bms/20080605005090/en 20080605005090en New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting Sun, 1 Jun 2008 19:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and http://www.businesswire.com/news/bms/20080601005070/en 20080601005070en ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer Sat, 31 May 2008 17:37:00 UT NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and http://www.businesswire.com/news/bms/20080531005025/en 20080531005025en Bristol-Myers Squibb Reaffirms 2008 Earnings Guidance Thu, 29 May 2008 20:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reaffirmed its 2008 earnings guidance for fully diluted http://www.businesswire.com/news/bms/20080529005922/en 20080529005922en Bristol-Myers Squibb to Acquire Kosan Biosciences Thu, 29 May 2008 13:22:00 UT PRINCETON, N.J. and HAYWARD, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Kosan Biosciences Inc. (NASDAQ: KOSN) announced today that the companies have signed a http://www.businesswire.com/news/bms/20080529005605/en 20080529005605en Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights Wed, 28 May 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a conference call at 4:30 p.m. (ET) on Monday, June 2 to http://www.businesswire.com/news/bms/20080528005190/en 20080528005190en Bristol-Myers Squibb to Present at Healthcare Conference Tue, 27 May 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Sanford Bernstein Conference on Friday, May 30, http://www.businesswire.com/news/bms/20080527005090/en 20080527005090en New Data on Bristol-Myers Squibb Oncology Compounds to Be Featured in More Than 100 Abstracts at ASCO 2008 Thu, 15 May 2008 13:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--More than 100 scientific abstracts on six Bristol-Myers Squibb Company (NYSE:BMY) oncology compounds http://www.businesswire.com/news/bms/20080515005644/en 20080515005644en U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features Thu, 8 May 2008 21:13:00 UT PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and http://www.businesswire.com/news/bms/20080508006491/en 20080508006491en Bristol-Myers Squibb to Present at Healthcare Conference Wed, 7 May 2008 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present today at the 33rd Annual Deutsche Bank Healthcare Conference. Lamberto Andreotti, http://www.businesswire.com/news/bms/20080507005223/en 20080507005223en Nordic Capital Fund VII and Avista Capital Partners Agree to Acquire ConvaTec Business for approximately $4.1 Billion Fri, 2 May 2008 19:59:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today it has signed a definitive agreement to sell http://www.businesswire.com/news/bms/20080502005742/en 20080502005742en Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes Tue, 29 Apr 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has agreed to sell $1.6 billion of senior unsecured notes: $600 million in aggregate principal amount of 5.450% notes due May http://www.businesswire.com/news/bms/20081215006474/en 20081215006474en Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company Thu, 24 Apr 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported strong double-digit net sales growth and solid earnings growth for the first quarter 2008 and reaffirmed 2008 earnings guidance. http://www.businesswire.com/news/bms/20081218006204/en 20081218006204en U.S. Food and Drug Administration Approves ORENCIA® (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older Tue, 8 Apr 2008 12:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ORENCIA® (abatacept) for reducing signs and symptoms in http://www.businesswire.com/news/bms/20081211006209/en 20081211006209en BARACLUDE® (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients Mon, 24 Mar 2008 12:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--New BARACLUDE® (entecavir) data presented today demonstrated a continued low incidence of resistance in nucleoside-naive patients through five years of treatment. In the http://www.businesswire.com/news/bms/20081211006247/en 20081211006247en Bristol-Myers Squibb to Present at Healthcare Conferences Mon, 17 Mar 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will present at the Cowen and Company 28th Annual Health Care Conference today. Brian Daniels, M.D., senior vice president, Global Development, will http://www.businesswire.com/news/bms/20081211006268/en 20081211006268en New 300mg Loading Dose Tablet For Plavix® Receives Positive Opinion From The European Committee For Medicinal Products (CHMP) Wed, 5 Mar 2008 13:00:00 UT PARIS & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the http://www.businesswire.com/news/bms/20081211006391/en 20081211006391en Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board Tue, 12 Feb 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the company's Board of Directors has elected James M. Cornelius chairman of the Board. Mr. Cornelius, who was named chief http://www.businesswire.com/news/bms/20081211006352/en 20081211006352en CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ® (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients Wed, 6 Feb 2008 13:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the CASTLE study, in which 300 mg of once-daily REYATAZ® (atazanavir sulfate) taken with 100 mg of ritonavir http://www.businesswire.com/news/bms/20081211006402/en 20081211006402en Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 Thu, 31 Jan 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the fourth quarter and twelve months ended December 31, 2007 and revised 2008 earnings guidance primarily to http://www.businesswire.com/news/bms/20081216006363/en 20081216006363en Bristol-Myers Squibb Names Togo D. West, Jr. to Board of Directors Tue, 22 Jan 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Togo D. West, Jr. has been elected to its Board of Directors, effective today. West will serve as a member of the Compensation http://www.businesswire.com/news/bms/20081214005033/en 20081214005033en Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2007 on January 31 Wed, 16 Jan 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the fourth quarter and full year of 2007 on Thursday, January 31. During a 10 a.m. (ET) conference call on Jan. 31, company http://www.businesswire.com/news/bms/20081214005035/en 20081214005035en Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging Tue, 8 Jan 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Avista Capital Partners, a leading private equity firm, announced today that Avista has completed its acquisition of Bristol-Myers Squibb Medical http://www.businesswire.com/news/bms/20081214005036/en 20081214005036en